Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet